{"id":575,"date":"2025-05-01T13:39:00","date_gmt":"2025-05-01T12:39:00","guid":{"rendered":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/?page_id=575"},"modified":"2025-05-01T14:31:22","modified_gmt":"2025-05-01T13:31:22","slug":"probiotic","status":"publish","type":"page","link":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/probiotic\/","title":{"rendered":"PD Probiotic"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Investigating the effects of B. Subtilis Bacteria on the microbiome in Parkinson’s Disease<\/h2>\n\n\n\n

This study explores whether a helpful gut bacterium, Bacillus subtilis<\/em> PXN21, can improve life for people with Parkinson\u2019s disease.<\/strong>

Researchers know that the mix of microbes in the gut (called the gut microbiome) can be different in people with Parkinson\u2019s disease than in those without.

This study looks at whether a helpful gut bacterium, Bacillus subtilis<\/em> PXN21, can improve life for people with Parkinson\u2019s disease (PD). Researchers know the mix of microbes in the gut\u2014called the gut microbiome\u2014often differs between people with Parkinson\u2019s disease and those without.

Adults with Parkinson\u2019s can join this trial, where they\u2019re randomly placed into two groups. One group takes a pill supplement containing B. subtilis<\/em> PXN21; the other takes a placebo pill that looks and tastes the same but has no active bacteria. During the study, researchers collect stool samples to track changes in each group\u2019s gut bacteria. They also measure movement symptoms (like tremors and stiffness), thinking skills (such as memory and problem-solving), and everyday activities (like dressing or eating).

The goal is to find out whether B. subtilis<\/em> PXN21 can improve the microbiome and ease PD symptoms. If the results are promising, this could lead to new gut-focused treatments for Parkinson\u2019s disease.<\/p>\n\n\n